Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 25, 2026
TickeronGET DAILY SIGNALS
Johnson & Johnson (JNJ): Can Shares Reach $300 (+10% Upside)?

Johnson & Johnson (JNJ): Can Shares Reach $300 (+10% Upside)?

Key Takeaways

  • Target in focus: $300, roughly 10% above Johnson & Johnson's recent price near $273 and matching the most bullish Wall Street price target.
  • Bullish case: Accelerating growth in Innovative Medicine, a maturing MedTech pipeline, and a prolonged rally that has lifted shares sharply off their 52-week low.
  • Key obstacle: $300 sits well above the Street's consensus target of roughly $255, implying the move depends on continued upward estimate revisions.
  • Technical backdrop: The all-time high near $275 is the first major resistance level to clear before $300 becomes realistic.
  • Bottom line: $300 is ambitious but not implausible over a multi-quarter horizon, contingent on sustained pipeline execution and favorable sentiment.

Why the $300 Level Matters

JNJ has quietly delivered one of the more remarkable large-cap healthcare recoveries of the past year. After trading near $173 in September 2025, the stock has climbed toward $273, putting its all-time high of roughly $275 within reach. As the shares flirt with record territory, a growing number of investors are asking whether the stock can push through the next major psychological milestone: $300.

The $300 level is not arbitrary. It represents the highest price target among the Wall Street analysts covering the company, a round-number threshold that captures retail attention, and a roughly 10% advance from current levels. That distance makes it a meaningful but not outlandish objective to debate.

Company Overview and Current Market Position

JNJ is a diversified healthcare conglomerate operating through two segments: Innovative Medicine (its pharmaceutical business) and MedTech (medical devices). The company carries a market capitalization of approximately $650 billion and trades at a price-to-earnings (P/E) ratio near 31, reflecting a premium multiple for what has historically been viewed as a defensive, slower-growth name.

The recent rerating reflects a meaningful shift in fundamentals. Innovative Medicine has delivered double-digit year-over-year growth, led by strength in oncology treatments such as DARZALEX, while the MedTech division continues to recover and expand its product portfolio, including progress on the OTTAVA robotic surgical system. Management has expressed confidence in its outlook, guided by full-year 2026 adjusted earnings per share (EPS) of roughly $11.43 to $11.63. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Drive the Next Leg Higher

Several catalysts could support a push toward $300. First, continued strength in Innovative Medicine, particularly in oncology and immunology, could keep revenue and EPS growth ahead of consensus expectations. A deeper pipeline — spanning treatments for multiple myeloma, lupus, and other conditions — provides multiple shots on goal for future growth.

Second, analysts have been consistently raising targets. Morgan Stanley upgraded the stock and lifted its price target to $262 from $200, citing stronger growth prospects relative to large-cap biopharma peers. This pattern of upward revisions, if it continues, could gradually pull the consensus target — currently near $255 — closer to the $300 mark.

Third, resolution of the company's long-running talc litigation has removed a significant overhang that had weighed on sentiment for years, allowing investors to focus on operating performance. From what I see, the pipeline momentum remains the key variable to watch.

What Could Prevent the Move

The primary obstacle is valuation and expectations. At a P/E near 31, the stock is no longer priced like a stodgy defensive name, which means any stumble in growth could trigger a de-rating. Patent expirations on key drugs remain a structural headwind, even if new products are offsetting those losses for now.

Additionally, the gap between the current price and the consensus analyst target is notable. With the average target near $255, the stock already trades above what most analysts consider fair value on a 12-month view. Reaching $300 would require the consensus itself to climb substantially, a process that typically unfolds only with repeated earnings beats and raised guidance.

Analyst Price Targets

Wall Street's views remain constructive but divided. The consensus 12-month price target sits near $255, with a low estimate around $190 and a high estimate of $300. The high target — associated with TD Cowen — aligns exactly with the level investors are now asking about. Notably, even the bullish $300 target implies only modest additional upside beyond the stock's all-time high, underscoring how far shares have already run.

Technical Levels That Matter

From a technical analysis perspective, the all-time high near $275 is the critical supply zone. A decisive break and hold above that level would establish new price discovery and could open the path toward $300. On the downside, the prior consolidation zone between roughly $255 and $265, along with the psychological $250 level, represents the first meaningful support area should momentum fade. I also checked this using Tickeron’s AI Pattern Search Engine to confirm the key levels.

Final Assessment

A move to $300 for JNJ is achievable but far from assured. The strongest arguments in favor are the company's improving growth profile, a pipeline with multiple catalysts, and the steady climb in analyst price targets. The biggest risks are the stock's already-rich valuation, looming patent expirations, and the fact that it now trades above the Street's consensus target. Investors should monitor quarterly revenue and EPS trends, pipeline readouts, and whether the shares can hold above their prior all-time high before any sustained push toward $300 becomes realistic.

Tracking Momentum with AI Daily Buy/Sell Signals

For traders monitoring whether JNJ can sustain its momentum toward $300, I find Tickeron’s AI Daily Buy/Sell Signals a practical way to stay on top of shifting conditions. The platform uses artificial intelligence to generate Buy, Sell, or Hold signals based on technical patterns and market behavior, helping me track opportunities and existing positions more efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: JNJ

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


JNJ in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026

The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 165 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.

The Aroon Indicator entered an Uptrend today. In 124 of 260 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 39 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 46%.

The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 21 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.

JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 17 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -7%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -2%. OGN experienced the highest price growth at 0%, while SCLX experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 39%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was 19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 33
Price Growth Rating: 44
SMR Rating: 59
Profit Risk Rating: 59
Seasonality Score: 22 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an investment holding company with interests in health care products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
One Johnson & Johnson Plaza
Phone
+1 732 524-0400
Employees
138200
Web
https://www.jnj.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.